Last reviewed · How we verify
Azilsartan Medoxomil and amlodipine
Azilsartan Medoxomil and amlodipine is a Angiotensin II receptor blocker + calcium channel blocker combination Small molecule drug developed by Takeda. It is currently in Phase 3 development for Hypertension. Also known as: Norvasc, TAK-491, Edarbi.
Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.
Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload. Used for Hypertension.
At a glance
| Generic name | Azilsartan Medoxomil and amlodipine |
|---|---|
| Also known as | Norvasc, TAK-491, Edarbi |
| Sponsor | Takeda |
| Drug class | Angiotensin II receptor blocker + calcium channel blocker combination |
| Target | AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Edema
- Fatigue
- Headache
- Hypotension
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B (PHASE1)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Azilsartan Circadian and Sleep Pressure (NA)
- Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension. (PHASE2, PHASE3)
- Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azilsartan Medoxomil and amlodipine CI brief — competitive landscape report
- Azilsartan Medoxomil and amlodipine updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Azilsartan Medoxomil and amlodipine
What is Azilsartan Medoxomil and amlodipine?
How does Azilsartan Medoxomil and amlodipine work?
What is Azilsartan Medoxomil and amlodipine used for?
Who makes Azilsartan Medoxomil and amlodipine?
Is Azilsartan Medoxomil and amlodipine also known as anything else?
What drug class is Azilsartan Medoxomil and amlodipine in?
What development phase is Azilsartan Medoxomil and amlodipine in?
What are the side effects of Azilsartan Medoxomil and amlodipine?
What does Azilsartan Medoxomil and amlodipine target?
Related
- Drug class: All Angiotensin II receptor blocker + calcium channel blocker combination drugs
- Target: All drugs targeting AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Also known as: Norvasc, TAK-491, Edarbi
- Compare: Azilsartan Medoxomil and amlodipine vs similar drugs
- Pricing: Azilsartan Medoxomil and amlodipine cost, discount & access